Retatrutide vs Mounjaro — Research Comparison | Regena

Mounjaro (tirzepatide) is a dual agonist — it engages GLP-1 and GIP receptors. Retatrutide adds a third mechanism, glucagon receptor activation. The glucagon-receptor arm is hypothesised to increase hepatic lipid oxidation and resting energy expenditure, which is the structural reason retatrutide effect sizes in phase-2 trials have outpaced earlier dual agonists.

Tirzepatide phase-2 (SURPASS programme) showed mean weight reductions of approximately 9-14% at 40 weeks across dose arms. Retatrutide phase-2 reported approximately 17.5% at 24 weeks and continued to trend downward at 48 weeks — a steeper trajectory than tirzepatide phase-2. No head-to-head phase-3 trial has yet been published; comparisons remain cross-study.

Both peptides are engineered for once-weekly cadence with elimination half-lives in the multi-day range. Tirzepatide t½ is ~5 days; retatrutide t½ is ~6 days. Both are reconstituted with bacteriostatic water and held under refrigeration in-use.

Storage is identical: lyophilised at 2–8 °C, reconstitute with bacteriostatic water, refrigerated in-use stability up to 28 days, aliquot before first freeze. Most research teams hold both peptides in the same fridge with identical SOPs.

Both compounds ship from Regena's Marbella facility with Janoshik HPLC and mass-spec COA per batch. The verification pipeline is identical — only the molecular target differs.

For a research team comparing incretin classes, the standard library covers all three generations: semaglutide (GLP-1 mono), tirzepatide (GLP-1/GIP dual) and retatrutide (GLP-1/GIP/glucagon triple). Holding all three lets a study isolate the marginal contribution of each receptor arm.